lcn2 Search Results


99
Thermo Fisher gene exp lcn2 mm01324470 m1
Gene Exp Lcn2 Mm01324470 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp lcn2 mm01324470 m1/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
gene exp lcn2 mm01324470 m1 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

93
Shanghai Korain Biotech Co Ltd human neutrophil gelatinase associated lipocalin
Human Neutrophil Gelatinase Associated Lipocalin, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human neutrophil gelatinase associated lipocalin/product/Shanghai Korain Biotech Co Ltd
Average 93 stars, based on 1 article reviews
human neutrophil gelatinase associated lipocalin - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

95
Proteintech anti lipocalin 2 lcn2
Anti Lipocalin 2 Lcn2, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti lipocalin 2 lcn2/product/Proteintech
Average 95 stars, based on 1 article reviews
anti lipocalin 2 lcn2 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

86
Thermo Fisher gene exp lcn2 mm01324472 g1
Gene Exp Lcn2 Mm01324472 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp lcn2 mm01324472 g1/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
gene exp lcn2 mm01324472 g1 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier

88
Thermo Fisher gene exp lcn2 hs01008571 m1
2-DG blocks the expression of multiple IL-1β-induced inflammatory genes in human astrocytes. Fold change of IL-1β ( A ), TNFα ( B ), C3 ( C ), or <t>LCN2</t> ( D ) mRNA transcript levels normalized to ACTB mRNA levels in total RNA isolated from human astrocytes. One-way ANOVA was performed to the determine effect of treatment on IL-1β [F (9, 10) = 505.5, p < 0.0001], TNFα [F (9, 10) = 96.72, p < 0.0001], C3 [F (9, 10) = 796.1, p < 0.0001], and LCN2 [F (9, 10) = 516.8, p < 0.0001]. A post hoc Tukey’s test was conducted with corrected p -values shown (** p < 0.01; *** p < 0.001 vs. vehicle; ^^^ p < 0.001 vs. IL-1β-treated cells).
Gene Exp Lcn2 Hs01008571 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp lcn2 hs01008571 m1/product/Thermo Fisher
Average 88 stars, based on 1 article reviews
gene exp lcn2 hs01008571 m1 - by Bioz Stars, 2026-03
88/100 stars
  Buy from Supplier

94
Thermo Fisher gene exp lcn2 hs00194353 m1
2-DG blocks the expression of multiple IL-1β-induced inflammatory genes in human astrocytes. Fold change of IL-1β ( A ), TNFα ( B ), C3 ( C ), or <t>LCN2</t> ( D ) mRNA transcript levels normalized to ACTB mRNA levels in total RNA isolated from human astrocytes. One-way ANOVA was performed to the determine effect of treatment on IL-1β [F (9, 10) = 505.5, p < 0.0001], TNFα [F (9, 10) = 96.72, p < 0.0001], C3 [F (9, 10) = 796.1, p < 0.0001], and LCN2 [F (9, 10) = 516.8, p < 0.0001]. A post hoc Tukey’s test was conducted with corrected p -values shown (** p < 0.01; *** p < 0.001 vs. vehicle; ^^^ p < 0.001 vs. IL-1β-treated cells).
Gene Exp Lcn2 Hs00194353 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp lcn2 hs00194353 m1/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
gene exp lcn2 hs00194353 m1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Boster Bio cxcr2 antibody
Spinal injection of TNF-α-activated astrocytes induces mechanical allodynia via Cx43-mediated CXCL1 release. (A) Intrathecal injection of TNF-α-activated astrocytes elicited persistent mechanical allodynia for >48 h. Note this allodynia is reduced by pretreatment of astrocytes with Cx43 small interfering RNA (1 µg/ml, 18 h). *P < 0.05, compared with TNF-α or TNF-α + non-targeting control small interfering RNA treated group; n = 6 mice/group. (B) ELISA analysis shows increased CXCL1 release in the CSF at 3 h after the intrathecal injection of TNF-α-activated astrocytes. *P < 0.05, compared with vehcile group; #P < 0.05, compared with non-activated astrocytes; n = 4 mice/group. (C) Intrathecal injection of a CXCL1 neutralizing antibody (4 µg) transiently and partially reversed mechanical allodynia, induced by TNF-α-treated astrocytes. *P < 0.05, compared with control IgG group; n = 6 mice/group. (D) Intrathecal injection of the <t>CXCR2</t> antagonist SB225002 (20 µg = 57 nmol) transiently and partially reversed mechanical allodynia, induced by TNF-α-activated astrocytes. *P < 0.05, compared with vehicle (PBS); n = 5–6 mice/group. All data are mean ± SEM. The differences between groups were analysed by ANOVA followed by Newman–Keuls test.
Cxcr2 Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cxcr2 antibody/product/Boster Bio
Average 93 stars, based on 1 article reviews
cxcr2 antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Proteintech elisa kit
Spinal injection of TNF-α-activated astrocytes induces mechanical allodynia via Cx43-mediated CXCL1 release. (A) Intrathecal injection of TNF-α-activated astrocytes elicited persistent mechanical allodynia for >48 h. Note this allodynia is reduced by pretreatment of astrocytes with Cx43 small interfering RNA (1 µg/ml, 18 h). *P < 0.05, compared with TNF-α or TNF-α + non-targeting control small interfering RNA treated group; n = 6 mice/group. (B) ELISA analysis shows increased CXCL1 release in the CSF at 3 h after the intrathecal injection of TNF-α-activated astrocytes. *P < 0.05, compared with vehcile group; #P < 0.05, compared with non-activated astrocytes; n = 4 mice/group. (C) Intrathecal injection of a CXCL1 neutralizing antibody (4 µg) transiently and partially reversed mechanical allodynia, induced by TNF-α-treated astrocytes. *P < 0.05, compared with control IgG group; n = 6 mice/group. (D) Intrathecal injection of the <t>CXCR2</t> antagonist SB225002 (20 µg = 57 nmol) transiently and partially reversed mechanical allodynia, induced by TNF-α-activated astrocytes. *P < 0.05, compared with vehicle (PBS); n = 5–6 mice/group. All data are mean ± SEM. The differences between groups were analysed by ANOVA followed by Newman–Keuls test.
Elisa Kit, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit/product/Proteintech
Average 93 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

92
Boster Bio antibodies anti ngal antibody
Effect of Melittin Attenuates sepsis-AKI. (a) H&E staining of kidney tissues from the Different groups. The red arrows denote the occurrence of tubular dilatation. The blue arrows highlight the swelling of renal tubular epithelial cells. Scale bars: 400 μm. (b) Tubular injury score. (c) Immunohistochemical staining of kidney with <t>primary</t> <t>antibodies</t> against <t>NGAL.</t> The areas marked with red arrows are NGAL-positive regions. Scale bars: 400 μm. (d) Average percentage of positive staining for NGAL per field.(n = 3). (e) Western blotting of NGAL in kidney tissues. (f) Plasma BUN levels. (g) Plasma creatinine levels. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, no significant difference between control and LPS group.
Antibodies Anti Ngal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies anti ngal antibody/product/Boster Bio
Average 92 stars, based on 1 article reviews
antibodies anti ngal antibody - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

87
Thermo Fisher gene exp lcn2 mm00809552 s1
Effect of Melittin Attenuates sepsis-AKI. (a) H&E staining of kidney tissues from the Different groups. The red arrows denote the occurrence of tubular dilatation. The blue arrows highlight the swelling of renal tubular epithelial cells. Scale bars: 400 μm. (b) Tubular injury score. (c) Immunohistochemical staining of kidney with <t>primary</t> <t>antibodies</t> against <t>NGAL.</t> The areas marked with red arrows are NGAL-positive regions. Scale bars: 400 μm. (d) Average percentage of positive staining for NGAL per field.(n = 3). (e) Western blotting of NGAL in kidney tissues. (f) Plasma BUN levels. (g) Plasma creatinine levels. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, no significant difference between control and LPS group.
Gene Exp Lcn2 Mm00809552 S1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 87/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp lcn2 mm00809552 s1/product/Thermo Fisher
Average 87 stars, based on 1 article reviews
gene exp lcn2 mm00809552 s1 - by Bioz Stars, 2026-03
87/100 stars
  Buy from Supplier

Image Search Results


2-DG blocks the expression of multiple IL-1β-induced inflammatory genes in human astrocytes. Fold change of IL-1β ( A ), TNFα ( B ), C3 ( C ), or LCN2 ( D ) mRNA transcript levels normalized to ACTB mRNA levels in total RNA isolated from human astrocytes. One-way ANOVA was performed to the determine effect of treatment on IL-1β [F (9, 10) = 505.5, p < 0.0001], TNFα [F (9, 10) = 96.72, p < 0.0001], C3 [F (9, 10) = 796.1, p < 0.0001], and LCN2 [F (9, 10) = 516.8, p < 0.0001]. A post hoc Tukey’s test was conducted with corrected p -values shown (** p < 0.01; *** p < 0.001 vs. vehicle; ^^^ p < 0.001 vs. IL-1β-treated cells).

Journal: Brain Sciences

Article Title: Caloric Restriction Mimetic 2-Deoxyglucose Reduces Inflammatory Signaling in Human Astrocytes: Implications for Therapeutic Strategies Targeting Neurodegenerative Diseases

doi: 10.3390/brainsci12030308

Figure Lengend Snippet: 2-DG blocks the expression of multiple IL-1β-induced inflammatory genes in human astrocytes. Fold change of IL-1β ( A ), TNFα ( B ), C3 ( C ), or LCN2 ( D ) mRNA transcript levels normalized to ACTB mRNA levels in total RNA isolated from human astrocytes. One-way ANOVA was performed to the determine effect of treatment on IL-1β [F (9, 10) = 505.5, p < 0.0001], TNFα [F (9, 10) = 96.72, p < 0.0001], C3 [F (9, 10) = 796.1, p < 0.0001], and LCN2 [F (9, 10) = 516.8, p < 0.0001]. A post hoc Tukey’s test was conducted with corrected p -values shown (** p < 0.01; *** p < 0.001 vs. vehicle; ^^^ p < 0.001 vs. IL-1β-treated cells).

Article Snippet: Gene expression was determined using RT 2 PCR TaqMan gene expression assays with the QuantStudio 3 sequence-detections system (Life Technologies TM ) using Taqman primers specific to IL-1β (cat. no. Hs01555410_m1), IL6 (cat. no. Hs00174131_m1), TNFα (cat. no. Hs00174128_m1), C3 (cat. no. Hs00163811_m1), and LCN2 (cat. no. Hs01008571_m1).

Techniques: Expressing, Isolation

2-DG blocks IL-1β-induced inflammatory gene expression in human astrocytes. IL-1β is a prototypic inflammatory cytokine that is relevant to many neurodegenerative diseases. IL-1β was used here to model neuroinflammation while 2-DG was used to mimic caloric restriction, a phenomenon relevant to fasting and exercise, both of which may have beneficial effects on the brain. Our findings indicate that 2-DG reduces the IL-1β-induced expression of inflammatory genes in astrocytes including, but not limited to, IL6, TNFα, C3, and LCN2. This finding may partially explain the beneficial effects of exercise, caloric restriction, and ketogenic diets. Future studies will further investigate the mechanisms through which 2-DG is reducing astrocyte inflammatory gene expression as well as the downstream effects on neuronal functioning and blood–brain barrier integrity.

Journal: Brain Sciences

Article Title: Caloric Restriction Mimetic 2-Deoxyglucose Reduces Inflammatory Signaling in Human Astrocytes: Implications for Therapeutic Strategies Targeting Neurodegenerative Diseases

doi: 10.3390/brainsci12030308

Figure Lengend Snippet: 2-DG blocks IL-1β-induced inflammatory gene expression in human astrocytes. IL-1β is a prototypic inflammatory cytokine that is relevant to many neurodegenerative diseases. IL-1β was used here to model neuroinflammation while 2-DG was used to mimic caloric restriction, a phenomenon relevant to fasting and exercise, both of which may have beneficial effects on the brain. Our findings indicate that 2-DG reduces the IL-1β-induced expression of inflammatory genes in astrocytes including, but not limited to, IL6, TNFα, C3, and LCN2. This finding may partially explain the beneficial effects of exercise, caloric restriction, and ketogenic diets. Future studies will further investigate the mechanisms through which 2-DG is reducing astrocyte inflammatory gene expression as well as the downstream effects on neuronal functioning and blood–brain barrier integrity.

Article Snippet: Gene expression was determined using RT 2 PCR TaqMan gene expression assays with the QuantStudio 3 sequence-detections system (Life Technologies TM ) using Taqman primers specific to IL-1β (cat. no. Hs01555410_m1), IL6 (cat. no. Hs00174131_m1), TNFα (cat. no. Hs00174128_m1), C3 (cat. no. Hs00163811_m1), and LCN2 (cat. no. Hs01008571_m1).

Techniques: Gene Expression, Expressing

Spinal injection of TNF-α-activated astrocytes induces mechanical allodynia via Cx43-mediated CXCL1 release. (A) Intrathecal injection of TNF-α-activated astrocytes elicited persistent mechanical allodynia for >48 h. Note this allodynia is reduced by pretreatment of astrocytes with Cx43 small interfering RNA (1 µg/ml, 18 h). *P < 0.05, compared with TNF-α or TNF-α + non-targeting control small interfering RNA treated group; n = 6 mice/group. (B) ELISA analysis shows increased CXCL1 release in the CSF at 3 h after the intrathecal injection of TNF-α-activated astrocytes. *P < 0.05, compared with vehcile group; #P < 0.05, compared with non-activated astrocytes; n = 4 mice/group. (C) Intrathecal injection of a CXCL1 neutralizing antibody (4 µg) transiently and partially reversed mechanical allodynia, induced by TNF-α-treated astrocytes. *P < 0.05, compared with control IgG group; n = 6 mice/group. (D) Intrathecal injection of the CXCR2 antagonist SB225002 (20 µg = 57 nmol) transiently and partially reversed mechanical allodynia, induced by TNF-α-activated astrocytes. *P < 0.05, compared with vehicle (PBS); n = 5–6 mice/group. All data are mean ± SEM. The differences between groups were analysed by ANOVA followed by Newman–Keuls test.

Journal: Brain

Article Title: Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice

doi: 10.1093/brain/awu140

Figure Lengend Snippet: Spinal injection of TNF-α-activated astrocytes induces mechanical allodynia via Cx43-mediated CXCL1 release. (A) Intrathecal injection of TNF-α-activated astrocytes elicited persistent mechanical allodynia for >48 h. Note this allodynia is reduced by pretreatment of astrocytes with Cx43 small interfering RNA (1 µg/ml, 18 h). *P < 0.05, compared with TNF-α or TNF-α + non-targeting control small interfering RNA treated group; n = 6 mice/group. (B) ELISA analysis shows increased CXCL1 release in the CSF at 3 h after the intrathecal injection of TNF-α-activated astrocytes. *P < 0.05, compared with vehcile group; #P < 0.05, compared with non-activated astrocytes; n = 4 mice/group. (C) Intrathecal injection of a CXCL1 neutralizing antibody (4 µg) transiently and partially reversed mechanical allodynia, induced by TNF-α-treated astrocytes. *P < 0.05, compared with control IgG group; n = 6 mice/group. (D) Intrathecal injection of the CXCR2 antagonist SB225002 (20 µg = 57 nmol) transiently and partially reversed mechanical allodynia, induced by TNF-α-activated astrocytes. *P < 0.05, compared with vehicle (PBS); n = 5–6 mice/group. All data are mean ± SEM. The differences between groups were analysed by ANOVA followed by Newman–Keuls test.

Article Snippet: The sections were then incubated overnight at 4°C with the following primary antibodies: GFAP antibody (1:1000, mouse; Millipore Bioscience Research Reagents), Cx43 antibody (1:1000, rabbit; Sigma), NeuN antibody (1:1000, mouse; Millipore Bioscience Research Reagents), CXCL1 (1: 200, rabbit; Boster), and CXCR2 antibody (1: 200, rabbit; Boster).

Techniques: Injection, Small Interfering RNA, Control, Enzyme-linked Immunosorbent Assay

CXCL1, upregulated in spinal cord astrocytes after nerve injury, enhances excitatory synaptic transmission in spinal cord neurons and maintains neuropathic pain via CXCR2. (A) Western blotting shows CXCL1 upregulation in the spinal cord dorsal horn 21 days after CCI. Right, quantification of Cx43 levels in the dorsal horn. The western blot results are presented as a fold of sham control. *P < 0.05, compared to sham control, Student’s t-test, n = 4 mice/group. (B) Intrathecal injection of SB 225002 (20 µg), 21 days after CCI, reduced CCI-induced mechanical allodynia in the late phase. *P < 0.05, compared with vehicle (saline), Student’s t-test, n = 6 mice/group. (C) Double immunostaining of CXCL1 and GFAP in the dorsal horn 21 days after CCI. Note CXCL1 is primarily colocalized with GFAP. Arrows indicate doubled-labelled cells. Scale bar = 50 µm. (D and E) CXCL1 superfusion (100 ng/ml) increases spontaneous EPSC frequency (revealed by patch clamp recordings) in lamina IIo neurons of spinal cord slices. (E) Spontaneous EPSC frequency. *P < 0.05, Student’s t-test, n = 5 neurons/group. (F and G) CCI (21 d) increases spontaneous EPSC frequency, which is reversed by the CXCR2 antagonist SB225002 (1 µM). *P < 0.05, Student’s t-test, n = 5 neurons/group.

Journal: Brain

Article Title: Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice

doi: 10.1093/brain/awu140

Figure Lengend Snippet: CXCL1, upregulated in spinal cord astrocytes after nerve injury, enhances excitatory synaptic transmission in spinal cord neurons and maintains neuropathic pain via CXCR2. (A) Western blotting shows CXCL1 upregulation in the spinal cord dorsal horn 21 days after CCI. Right, quantification of Cx43 levels in the dorsal horn. The western blot results are presented as a fold of sham control. *P < 0.05, compared to sham control, Student’s t-test, n = 4 mice/group. (B) Intrathecal injection of SB 225002 (20 µg), 21 days after CCI, reduced CCI-induced mechanical allodynia in the late phase. *P < 0.05, compared with vehicle (saline), Student’s t-test, n = 6 mice/group. (C) Double immunostaining of CXCL1 and GFAP in the dorsal horn 21 days after CCI. Note CXCL1 is primarily colocalized with GFAP. Arrows indicate doubled-labelled cells. Scale bar = 50 µm. (D and E) CXCL1 superfusion (100 ng/ml) increases spontaneous EPSC frequency (revealed by patch clamp recordings) in lamina IIo neurons of spinal cord slices. (E) Spontaneous EPSC frequency. *P < 0.05, Student’s t-test, n = 5 neurons/group. (F and G) CCI (21 d) increases spontaneous EPSC frequency, which is reversed by the CXCR2 antagonist SB225002 (1 µM). *P < 0.05, Student’s t-test, n = 5 neurons/group.

Article Snippet: The sections were then incubated overnight at 4°C with the following primary antibodies: GFAP antibody (1:1000, mouse; Millipore Bioscience Research Reagents), Cx43 antibody (1:1000, rabbit; Sigma), NeuN antibody (1:1000, mouse; Millipore Bioscience Research Reagents), CXCL1 (1: 200, rabbit; Boster), and CXCR2 antibody (1: 200, rabbit; Boster).

Techniques: Transmission Assay, Western Blot, Control, Injection, Saline, Double Immunostaining, Patch Clamp

Schematic of working hypothesis for astrocytic Cx43-mediated late-phase neuropathic pain. CCI induces a persistent upregulation of Cx43 in spinal cord astrocytes. Cx43 expression and activity is also upregulated by TNF-α, secreted from microglia. Upregulation of Cx43 hemichannel activities results in CXCL1 release. Astrocytic CXCL1 secretion activates CXCR2 on neurons (central terminals of primary sensory neurons and spinal cord neurons), leading to enhanced excitatory synaptic transmission in nociceptive neurons (e.g. lamina IIo excitatory interneurons) and sustained neuropathic pain in the late-phase. Additionally, CXCL1 can also be secreted from intact or injured primary afferents in the spinal cord especially in the early phase of CCI.

Journal: Brain

Article Title: Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice

doi: 10.1093/brain/awu140

Figure Lengend Snippet: Schematic of working hypothesis for astrocytic Cx43-mediated late-phase neuropathic pain. CCI induces a persistent upregulation of Cx43 in spinal cord astrocytes. Cx43 expression and activity is also upregulated by TNF-α, secreted from microglia. Upregulation of Cx43 hemichannel activities results in CXCL1 release. Astrocytic CXCL1 secretion activates CXCR2 on neurons (central terminals of primary sensory neurons and spinal cord neurons), leading to enhanced excitatory synaptic transmission in nociceptive neurons (e.g. lamina IIo excitatory interneurons) and sustained neuropathic pain in the late-phase. Additionally, CXCL1 can also be secreted from intact or injured primary afferents in the spinal cord especially in the early phase of CCI.

Article Snippet: The sections were then incubated overnight at 4°C with the following primary antibodies: GFAP antibody (1:1000, mouse; Millipore Bioscience Research Reagents), Cx43 antibody (1:1000, rabbit; Sigma), NeuN antibody (1:1000, mouse; Millipore Bioscience Research Reagents), CXCL1 (1: 200, rabbit; Boster), and CXCR2 antibody (1: 200, rabbit; Boster).

Techniques: Expressing, Activity Assay, Transmission Assay

Effect of Melittin Attenuates sepsis-AKI. (a) H&E staining of kidney tissues from the Different groups. The red arrows denote the occurrence of tubular dilatation. The blue arrows highlight the swelling of renal tubular epithelial cells. Scale bars: 400 μm. (b) Tubular injury score. (c) Immunohistochemical staining of kidney with primary antibodies against NGAL. The areas marked with red arrows are NGAL-positive regions. Scale bars: 400 μm. (d) Average percentage of positive staining for NGAL per field.(n = 3). (e) Western blotting of NGAL in kidney tissues. (f) Plasma BUN levels. (g) Plasma creatinine levels. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, no significant difference between control and LPS group.

Journal: Redox Report : Communications in Free Radical Research

Article Title: Melittin alleviates sepsis-induced acute kidney injury by promoting GPX4 expression to inhibit ferroptosis

doi: 10.1080/13510002.2023.2290864

Figure Lengend Snippet: Effect of Melittin Attenuates sepsis-AKI. (a) H&E staining of kidney tissues from the Different groups. The red arrows denote the occurrence of tubular dilatation. The blue arrows highlight the swelling of renal tubular epithelial cells. Scale bars: 400 μm. (b) Tubular injury score. (c) Immunohistochemical staining of kidney with primary antibodies against NGAL. The areas marked with red arrows are NGAL-positive regions. Scale bars: 400 μm. (d) Average percentage of positive staining for NGAL per field.(n = 3). (e) Western blotting of NGAL in kidney tissues. (f) Plasma BUN levels. (g) Plasma creatinine levels. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, no significant difference between control and LPS group.

Article Snippet: Incubation was performed with the primary antibodies anti-NGAL antibody (PB9609, Boster, China) and anti-4-HNE antibody (AO2685-4, Boster, China).

Techniques: Staining, Immunohistochemical staining, Western Blot, Clinical Proteomics, Control